Elevate Chicago

Clinical education

Testosterone and your face.

A face that has changed is a real, visible signal — and it is a reason to measure, not a diagnosis.

What testosterone doesn’t do.

Androgens build the male skull once, at puberty. Brow ridge, jaw width and chin projection are set then, and adult testosterone does not remodel bone. What it changes is everything sitting on top of it — fat, fluid, skin and hair. That is why a face can look different within months without a single millimetre of bone moving.

Four things that actually change.

Open each one for the mechanism, the rough timeline, and the limit of what the evidence supports.

Androgens shift fat storage away from the subcutaneous, oestrogen-patterned depots — cheeks, jawline, submental area — toward visceral storage. The buccal and jowl pads thin, so the underlying bone reads as sharper. The bone itself is unchanged.

Timeline. Usually noticeable between 3 and 9 months, and it tracks body composition rather than dose.

What we know. Testosterone reliably changes fat distribution in hypogonadal men.
What we don’t. There is no evidence that the size of the facial change can be predicted from a starting level or a dose.

Testosterone aromatizes to oestradiol, which drives sodium and water retention. Higher oestradiol tends to mean a fuller, softer, puffier face — particularly under the eyes and along the jaw. This moves in both directions and can change within days.

Timeline. Days to weeks. It commonly peaks a few days after an injection and settles before the next one.

What we know. Aromatization to oestradiol and fluid shift are well described.
What we don’t. No oestradiol number reliably predicts facial puffiness in an individual, and treating a number rather than a symptom causes its own problems.

Androgens increase sebaceous gland size and sebum output and modestly increase dermal thickness and collagen. Pores read as larger, texture reads as coarser, and acne on the face, chest and back is a common early effect.

Timeline. Sebum changes within 4 to 8 weeks. Skin thickness changes over many months.

What we know. Sebum production and acne rise with androgen exposure; this is dose-related.
What we don’t. Whether therapy makes any individual's skin look better or worse over years has not been established.

Testosterone converts to DHT via 5-alpha reductase. On the face and body, DHT drives terminal hair growth. On a genetically susceptible scalp, the same hormone miniaturizes follicles. The direction of the effect is set by follicle genetics, not by dose.

Timeline. Beard and body changes over 6 to 24 months. Scalp changes are slower and easy to miss early.

What we know. DHT is central to both beard growth and androgenetic hair loss.
What we don’t. There is no test that tells you in advance which scalp will respond badly. Family history is the best available signal, and it is imperfect.

The panel.

Three tiers: what drives the face, what else causes the same face, and what has to be safe before and during treatment.

The anchor measurement. Low total testosterone is the only finding that makes facial change a hormonal question at all.

Draw between 7 and 10 a.m., fasted where practical. LC-MS/MS is preferred over immunoassay.

The fraction actually available to tissue. Total can look adequate while free is low, particularly when SHBG is high.

Calculated free testosterone from total, SHBG and albumin is more reliable than most direct assays.

Determines how much testosterone is bound and unavailable. Explains why two men with the same total feel and look different.

Rises with age, thyroid excess and liver disease; falls with insulin resistance and obesity.

The fluid and puffiness driver, and the marker most often misread. Too low is as much a problem as too high.

Request the sensitive LC-MS/MS assay. Standard immunoassay is unreliable in men.

Drives beard density and, on a susceptible scalp, follicle miniaturization.

Interpreted against total testosterone rather than alone; not required for every patient.

Separate a testicular cause from a pituitary or hypothalamic one. This changes what is treated, not just how.

Draw with the same morning sample as total testosterone.

Thyroid disease produces facial puffiness, skin change and hair thinning with entirely normal testosterone.

Check before attributing any of those findings to androgens.

Cortisol excess produces facial fullness and skin thinning — the classic mimic of a 'hormonal' face.

Timed morning draw; abnormal results need confirmatory testing before conclusions.

Elevated prolactin suppresses testosterone and can indicate a pituitary cause that testosterone therapy would mask rather than treat.

Avoid drawing after exercise, nipple stimulation or significant stress.

Insulin resistance both lowers testosterone and independently changes facial fat and skin.

Fasting sample. Often the finding that actually explains the change.

Iron overload damages the pituitary and gonads; iron deficiency causes hair shedding that looks androgenic.

Ferritin is an acute-phase reactant — interpret with CRP.

The most common reason testosterone therapy has to be reduced or paused.

Baseline, then at 3 and 6 months, then annually.

Required before starting in men over 40 and monitored on therapy.

Baseline, 3 to 6 months, then per age-appropriate schedule.

Therapy can lower HDL. Worth knowing where you started.

Fasting baseline, repeat at 6 to 12 months.

Liver and kidney function, electrolytes and albumin — albumin is also needed to calculate free testosterone.

Baseline and annually.

Not a lab, but it changes on therapy and belongs in the same review as the panel.

Home readings over two weeks beat one clinic reading.

Reference ranges vary by laboratory and by assay, so a result is only meaningful against the range printed on your own report. A single low morning result should be confirmed on a second draw before anything is decided.

Two men on the same dose get different faces.

Fat distribution differs. How much testosterone aromatizes to oestradiol differs. SHBG differs, so the free fraction differs. Follicle genetics differ, so the same DHT thickens one beard and thins another scalp. None of that is visible from a dose.

Which is why the answer is a panel, not a protocol.

Book a consultation

Elevate Chicago clinicians are licensed in Illinois, Florida, New York, and Texas. We’re expanding — join the waitlist and we’ll contact you when we can see patients in your state.

Testosterone is FDA-approved for the treatment of hypogonadism. Use for appearance is off-label. This page is educational and is not medical advice or a treatment recommendation. Reviewed by the Elevate Clinical Team.